25 Apr Complix to Present at PEGS 2017
Hasselt, April 25, 2017 – Complix, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™, announces that its CSO, Dr Yvonne McGrath, will be presenting their most recent developments on Alphabodies against intracellular targets at the 13th Annual PEGS Meeting in Boston, May 1-5. In her presentation entitled “Alphabodies as inhibitors of intracellular protein-protein interactions” Dr McGrath will give an overview of recent progress that Complix has achieved in developing cell penetrating Alphabodies (CPABs) acting on important intracellular cancer targets.
Details of the talk are as follows:
- Title: “Alphabodies as inhibitors of intracellular protein-protein interactions”
- Session: “Antibodies for Cancer Therapy”
- Time: 2nd of May at 4:55 PM
Complix is a biopharmaceutical company developing a pipeline of novel biotherapeutics, called Alphabodies™, mainly focused on oncology and autoimmune diseases.
Alphabodies are a revolutionary class of protein therapeutics that have the potential to address a wide range of disease targets, in particular intracellular targets that are considered undruggable by current drug formats, such as antibodies or small chemicals.
Complix is building a portfolio of Alphabody based therapeutics that act on a variety of intractable intracellular targets and is working in collaboration with pharma companies to create novel first-in-class therapeutics that have the potential to cure severe diseases with high medical need, including cancer. In December 2015 Complix signed a strategic collaboration with Merck & Co to develop novel Alphabody based therapeutics against two intracellular cancer targets. Under the terms of this deal Complix will be eligible to receive up to $280 million in upfront and development and regulatory milestones as well as tiered mid-single digit royalties on global sales revenues.
Complix NV (Belgium) and its affiliate Complix SA (Luxembourg) have established a strong intellectual property position protecting the Alphabody™ platform and its emerging product portfolio through the filing of multiple broad patent applications. Since its founding in 2008 Complix has raised a total of more than €20 million in venture financing, including a €12 million B round in June 2013 and a €7 million Series A equity round in 2010.
Dr. Yvonne McGrath, CSO
Tel. +32 9 261 69 40